Skip to main content
Clinical Trials/NCT04390555
NCT04390555
Unknown
Not Applicable

COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry

University of Zurich1 site in 1 country1,500 target enrollmentApril 30, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
University of Zurich
Enrollment
1500
Locations
1
Primary Endpoint
In-hospital mortality.
Last Updated
5 years ago

Overview

Brief Summary

Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease.

Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry.

Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.

Registry
clinicaltrials.gov
Start Date
April 30, 2020
End Date
July 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult inpatients (≥18 years old) with laboratory-confirmed COVID-19.

Exclusion Criteria

  • Age \<18 years old.
  • Outpatients.

Outcomes

Primary Outcomes

In-hospital mortality.

Time Frame: Hospitalization period, assessed up to 30 days

All-cause and cardiovascular mortality during index hospitalization.

Secondary Outcomes

  • Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.(3 months)
  • The duration of hospitalization.(Hospitalization period, assessed up to 30 days)
  • The length of stay in the intensive care unit.(Hospitalization period in the ICU, assessed up to 30 days)
  • The need and duration of invasive mechanical ventilation.(Hospitalization period, assessed up to 30 days)
  • Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.(6 months)

Study Sites (1)

Loading locations...

Similar Trials